Thursday, June 25, 2026
🇺🇸 FDA

Clinical Tools · Anticoagulation · Atrial Fibrillation

HAS-BLED Score Calculator

Calculate major bleeding risk on oral anticoagulation using the standard HAS-BLED score. Built for AFib pathway assessment, anticoagulant trial safety context, and linkage to stroke-risk scoring with CHA₂DS₂-VASc.

Quick Answer

The HAS-BLED score estimates major bleeding risk on oral anticoagulation in atrial fibrillation from hypertension, abnormal renal/hepatic function, stroke history, bleeding predisposition, labile INR, age, drugs, and alcohol (0–9 points). Scores ≥3 flag high bleeding risk warranting closer follow-up — not automatic anticoagulation contraindication. Pair with CHA₂DS₂-VASc stroke risk for balanced AFib pathway decisions in clinical and anticoagulant trial contexts.

HAS-BLED score
Total = H + Arenal + Aliver + S + B + L + E + Ddrugs + Dalcohol
Each criterion scores 0 or 1 point. Maximum 9. ≥3 = high bleeding risk (educational interpretation).

Calculate HAS-BLED Score

Select all criteria that apply to the patient. Each selected criterion adds 1 point to the total score.

HAS-BLED criteria

For DOAC-treated patients, the labile INR (L) criterion does not apply—leave it unchecked.

Bleeding risk

-

-

-

Total score
-
/ 9 points
Criteria selected
-
of 9

How to Use the HAS-BLED Calculator

1
Review the patient's clinical history, laboratory values, medications, and blood pressure control.
2
Select each HAS-BLED criterion that applies. For DOAC patients, omit the labile INR (L) criterion.
3
Calculate the total score (0–9) and review whether it falls below or at/above the ≥3 high-risk threshold.
4
Use the score alongside CHA₂DS₂-VASc stroke-risk assessment, address modifiable factors, and follow institutional anticoagulation protocols—not as a standalone treatment decision.

Worked Example

Example calculation

Patient: 72-year-old with atrial fibrillation on warfarin, SBP 168 mmHg on two agents, creatinine 1.8 mg/dL, no liver disease, no prior stroke, no bleeding history, TTR 55%, taking aspirin, no alcohol excess.

Criteria met: H (hypertension +1), L (labile INR +1), E (age >65 +1), D (aspirin +1).

Total HAS-BLED: 4 points — high bleeding risk (≥3). Consider blood pressure optimization, aspirin/anticoagulation review, and closer INR monitoring per protocol.

HAS-BLED Interpretation Bands

Low bleeding risk 0 – 2 points

Lower estimated major bleeding risk on anticoagulation. Standard monitoring per local AFib pathway.

High bleeding risk ≥ 3 points

Higher estimated major bleeding risk. Prompt closer follow-up, modifiable risk-factor review, and careful anticoagulant selection—not automatic contraindication.

Anticoagulant Safety Endpoints for Pharma Professionals

Phase 3 anticoagulant trials in atrial fibrillation and venous thromboembolism report major bleeding, clinically relevant non-major bleeding (CRNMB), and intracranial hemorrhage as key safety outcomes. HAS-BLED ≥3 at baseline often appears in patient demographics tables and may stratify bleeding event rates in subgroup analyses.

Sponsors designing AFib or anticoagulation programs should document both stroke risk (CHA₂DS₂-VASc) and bleeding risk (HAS-BLED) at enrollment. Safety endpoints in trial protocols typically specify adjudicated major bleeding per ISTH or protocol-defined criteria—not HAS-BLED score alone. Use our CHA₂DS₂-VASc Score Calculator for complementary stroke-risk assessment.

Post-marketing pharmacovigilance teams monitoring anticoagulant bleeding signals may cross-reference baseline HAS-BLED distributions with spontaneous report disproportionality. See our Signal Detection Metrics Calculator for PRR/ROR screening context.

DOAC vs Warfarin Considerations

HAS-BLED was validated primarily in warfarin-treated AF cohorts. The labile INR (L) component reflects poor time-in-therapeutic-range on warfarin (TTR <60%) and does not apply to direct oral anticoagulants (DOACs). When assessing DOAC-treated patients, score the remaining eight criteria.

DOAC trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF) demonstrated favorable or comparable bleeding profiles versus warfarin, but major bleeding remains a critical safety endpoint. Renal function (A criterion) is particularly relevant for DOAC dosing—dabigatran, rivaroxaban, and edoxaban require dose adjustment at lower creatinine clearance thresholds per label.

Abnormal liver function (second A criterion) overlaps with cirrhosis pathways assessed by Child-Pugh class. For hepatic impairment context in drug development, see our Child-Pugh Score Calculator.

Limitations and Caveats

HAS-BLED has moderate c-statistic for major bleeding prediction (~0.6–0.7 in validation cohorts) and may over-estimate bleeding risk, particularly when age and prior stroke—factors shared with CHA₂DS₂-VASc—are present. A high HAS-BLED score should prompt risk-factor modification, not reflex anticoagulation withdrawal when stroke risk is substantial.

The score does not capture fall risk, frailty, thrombocytopenia severity, planned surgery, or genetic bleeding predispositions. Labile INR applies only to warfarin. Always integrate clinical context, concomitant medications, and patient preferences.

HAS-BLED estimates bleeding risk on anticoagulation; it does not assess acute coronary syndrome risk. For chest pain triage in emergency pathways, see our HEART Score Calculator.

Interpretation Reference Table

HAS-BLED score Risk category Major bleeding risk Typical action
0 Low Lowest Standard anticoagulation monitoring per AFib pathway
1 – 2 Low Low to moderate Continue anticoagulation with routine follow-up; address modifiable factors if present
3 – 4 High Moderate to high Closer monitoring, review concomitant drugs, optimize blood pressure and alcohol use
5 – 9 High High Intensified follow-up, specialist referral, careful anticoagulant selection; do not withhold solely on score

Evidence & sources

Frequently Asked Questions

The HAS-BLED score estimates major bleeding risk in patients on oral anticoagulation, especially for atrial fibrillation. It assigns one point each for hypertension (uncontrolled SBP >160), abnormal renal or liver function, prior stroke, bleeding history or predisposition, labile INR on warfarin, age >65, drugs predisposing to bleeding, and alcohol excess. The maximum score is 9.
Each of the nine HAS-BLED criteria contributes 1 point if present: H (hypertension uncontrolled, SBP >160), A (abnormal renal: dialysis, transplant, or Cr >2.26 mg/dL), A (abnormal liver: cirrhosis or bilirubin >2× ULN with AST/ALT/AP >3× ULN), S (prior stroke), B (bleeding history or predisposition), L (labile INR with TTR <60% on warfarin), E (age >65), D (antiplatelet agents or NSAIDs), and D (alcohol ≥8 drinks/week). Sum the points for the total score.
A score ≥3 is commonly interpreted as high bleeding risk on anticoagulation in educational and guideline contexts. It flags patients who may need closer follow-up, bleeding-risk mitigation, and careful anticoagulant selection—but it does not by itself mandate withholding anticoagulation when stroke risk is substantial.
CHA₂DS₂-VASc estimates stroke risk and guides anticoagulation initiation; HAS-BLED estimates bleeding risk and guides monitoring and risk modification. They answer different questions and are often used together. A patient may have high stroke risk (CHA₂DS₂-VASc ≥2) and elevated bleeding risk (HAS-BLED ≥3); clinical decisions weigh both scores alongside patient values and reversible risk factors.
ORBIT, ATRIA, and HEMORR₂HAGES are alternative bleeding-risk models validated in different cohorts. HAS-BLED is the most widely cited in AF guidelines and trial literature because of its simplicity and broad adoption, but no single score perfectly predicts bleeding. Choice of score may depend on local protocol, available variables, and whether the patient is on warfarin versus a DOAC.
HAS-BLED was developed and validated primarily in warfarin-treated atrial fibrillation cohorts. The labile INR (L) component applies specifically to warfarin (TTR <60%). For DOAC-treated patients, omit the L criterion or score it as absent; the remaining eight factors still provide useful bleeding-risk context, though direct validation for DOAC-specific bleeding rates may differ from warfarin-era data.
No. HAS-BLED ≥3 identifies patients at higher bleeding risk who warrant closer monitoring and risk-factor modification—not automatic anticoagulation contraindication. Guidelines emphasize that high bleeding risk often correlates with high stroke risk; the appropriate response is to address modifiable factors (blood pressure, alcohol, interacting drugs) and select anticoagulation carefully rather than withhold stroke prevention.
AFib management programs, anticoagulation clinics, and integrated care pathways use HAS-BLED at enrollment to stratify follow-up intensity, flag patients for pharmacist review, and document bleeding-risk assessment. Pharma-sponsored patient-support or hub programs may reference HAS-BLED in HCP education materials to reinforce that bleeding risk assessment complements stroke-risk scoring.
Phase 3 anticoagulant trials report major bleeding, clinically relevant non-major bleeding, and intracranial hemorrhage as primary or key secondary safety endpoints. HAS-BLED may appear in baseline characteristics tables, subgroup analyses (e.g., HAS-BLED ≥3 vs <3), or as a covariate in bleeding-risk models. It helps sponsors contextualize bleeding event rates against expected risk in enrolled populations.
HAS-BLED has moderate predictive accuracy for major bleeding and may over-predict bleeding in some populations. It includes age >65 and prior stroke—factors also linked to stroke risk—creating overlap with CHA₂DS₂-VASc. The labile INR criterion is warfarin-specific. It does not capture all bleeding determinants (e.g., frailty, fall risk, thrombocytopenia) and should not replace clinical judgment.
HAS-BLED was validated for major bleeding broadly, not exclusively intracranial hemorrhage. Prior stroke and age >65 are associated with ICH risk, but HAS-BLED should not be used as a standalone ICH prediction tool. Anticoagulant trials report ICH as a separate safety endpoint; subgroup analyses by HAS-BLED may be exploratory rather than definitive.
No. HAS-BLED is a screening and stratification aid, not a substitute for comprehensive assessment of bleeding history, concomitant medications, renal/hepatic function, fall risk, planned procedures, and patient preferences. Medication and monitoring decisions must follow approved labels, institutional protocols, and specialist assessment.

Related Tools

C2V CHA₂DS₂-VASc Score HEART HEART Score CP Child-Pugh Score SD Signal Detection

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.